Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
Abroad (travel likely)RecruitingEARLY_PHASE1
Conditions
Epithelial Tumors, Malignant · Malignant Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Vall d'Hebron Institute of Oncology, Barcelona, Spain
Contact: Principal Investigator (Elena Garralda, MD)Vladimir Galvão de Aguiar, MD (Sub-investigator)
Study leads
Elena Garralda
Principal Investigator
Vall d'Hebron Institute of Oncology